Global Polio Eradication

What Global Polio Eradication does

The Global Polio Eradication Initiative (GPEI) is a public-private partnership founded in 1988 by the World Health Assembly and hosted by the World Health Organization in Geneva, Switzerland. Its mandate is the global eradication of poliovirus through vaccination, disease surveillance, and outbreak response. Six core partners share responsibility: the World Health Organization (WHO), Rotary International, the U.S. Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), the Bill & Melinda Gates Foundation, and Gavi, the Vaccine Alliance (the sixth partner since 2019). GPEI does not sell products; it coordinates, funds, and operationalizes the supply of oral and inactivated polio vaccines (OPV variants including bOPV, mOPV, and the genetically stabilized nOPV2, plus IPV), the Global Polio Laboratory Network of 145 facilities processing more than 100,000 stool samples per year, acute flaccid paralysis surveillance, and the digital dashboards that track wild poliovirus and variant cases and forecast vaccine requirements.

GPEI's operating model is donation-funded rather than commercial. Financing comes from sovereign donors, philanthropic commitments (Bill & Melinda Gates Foundation US$1.2B, Mohamed bin Zayed US$140M, Bloomberg Philanthropies US$100M, Rotary International cumulative US$2.7B+), private sector partners, and in-kind contributions from core partners and the Global Polio Laboratory Network. Its 2022–2029 strategy implementation budget of US$6.9B was revised upward in 2024 from an initial horizon that ended in 2026, and a US$1.9B replenishment was announced at Abu Dhabi Finance Week in December 2025. Programmatic delivery is scaled through UNICEF's procurement and cold-chain system, distributed across 200+ countries, supported by approximately 20 million volunteers and, during synchronized campaigns, ~34 million community health workers.

GPEI's competitive position is anchored in regulatory authority (it sits within WHO's IHR 2005 mandate and holds formal certification power for eradicating polio regions, last exercised with the African Region in 2020 and the South-East Asia Region in 2014), a globally coordinated distribution network, and a multi-decade data and laboratory asset base. As of 2025, wild poliovirus type 1 remains endemic in only two countries (Afghanistan and Pakistan, down from 125 in 1988), while variant poliovirus outbreaks are active in more than 18 countries, framing both the residual mission and the case for continued program scale.

Name

Global Polio Eradication

Legal name

Global Polio Eradication Initiative

Website

https://polioeradication.org

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

1–10 employees

Short description

The Global Polio Eradication Initiative (GPEI) is a WHO-hosted public-private partnership coordinating six core partners to deliver polio vaccination, surveillance, and outbreak response across 200+ countries. It was founded in 1988 and is funded by sovereign, philanthropic, and in-kind donations rather than commercial revenue.

Ownership category

akta.pro rank

Product category

Global Health Partnership

NAICS

Administration of Public Health Programs (92312)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

National/State/Local Immunization Program Offices (HLAJAHAA)

akta.pro secondary industries

Mass Vaccination & Community Outreach Operations (PODs/Mobile Clinics) (HLAJAHAD), Vaccine Policy, Advisory Committees & Program Governance (HLAJAHAJ), Immunization & Vaccination Programs Administration (BPAIAJAD), Immunization Program Evaluation & Coverage Assessment (HLAJANAH)

Keywords

• Polio immunization programs
• Vaccine procurement and logistics
• Disease surveillance networks
• Global health partnerships
• Outbreak response coordination

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Government Contributions: National governments contribute funding through WHO and UNICEF for polio eradication activities in their countries. Governments including Pakistan, Germany, USA contribute to the global program.
2. Philanthropic Donations: Major philanthropies including Gates Foundation ($1.2B pledged in 2025), Bloomberg Philanthropies ($100M), and Mohamed bin Zayed Foundation for Humanity ($140M) provide significant funding.
3. Private Sector Donations: Rotary International contributes through PolioPlus program, having contributed over $2.7 billion. Individual donors contribute through the donation platform.
4. In-Kind Contributions: Volunteer time from health workers, community mobilizers, and polio workers in implementing countries. Estimated value approximately equal to international financial contributions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

GPEI coordinates worldwide polio vaccination and surveillance through national immunization programs (NIPs) and supplementary immunization activities (SIAs). It administers polio vaccines — including Oral Polio Vaccine (OPV), Inactivated Polio Vaccine (IPV), and Novel Oral Polio Vaccine type 2 (nOPV2) — to children under 5, conducts poliovirus surveillance via Acute Flaccid Paralysis (AFP) reporting, environmental surveillance (sewage testing), and the Global Polio Laboratory Network, and coordinates rapid outbreak response across 200+ countries to achieve and sustain the eradication of all forms of poliovirus.

Product overview

The Global Polio Eradication Initiative (GPEI) is a public-private partnership led by national governments with six core partners (WHO, Rotary, CDC, UNICEF, Gates Foundation, Gavi) that operates as a coordinated global health program rather than a unified software platform. The initiative's portfolio consists of polio vaccines (Oral Polio Vaccines including bOPV, nOPV2, mOPV variants; and Inactivated Polio Vaccine/IPV), surveillance and monitoring tools (Wild Poliovirus Count Dashboard, VDPV Count Dashboard, Polio Surveillance System), planning tools (Polio Vaccine Forecasting Dashboard 2026-2030), outbreak response capabilities (SOPs, outbreak preparedness frameworks), research programs (antivirals, clinical trials, seroprevalence surveys), and strategic frameworks (Sustaining a Polio-free World Strategy, containment guidance). The core product offering centers on vaccine delivery and disease surveillance systems to achieve and maintain global polio eradication.

Differentiator

Problem solved

Functional benefit

Products and services

• Oral Polio Vaccine (OPV) Safe and effective oral vaccine containing attenuated polioviruses that stops person-to-person spread of poliovirus; administered to children during National Immunization Days and supplementary immunization activities in endemic and at-risk countries.
• Novel Oral Polio Vaccine Type 2 (nOPV2) Next-generation monovalent oral polio vaccine type 2 providing comparable individual protection to mOPV2 while being more genetically stable and less likely to seed new type 2 variant outbreaks; first vaccine to receive WHO Emergency Use Listing.
• Bivalent Oral Polio Vaccine (bOPV) OPV formulation containing type 1 and 3 serotypes without type 2 protection; used in routine immunization schedules and outbreak response since the 2016 switch from trivalent OPV.
• Monovalent Oral Polio Vaccine (mOPV) Single-serotype OPV formulations (mOPV1, mOPV2, mOPV3) reserved for response to respective outbreaks only; mOPV2 stockpiles are maintained for type 2 variant outbreak response.
• Inactivated Polio Vaccine (IPV) Injectable vaccine containing inactivated (killed) poliovirus strains of all three types; produces blood antibodies against all serotypes with no risk of vaccine-associated paralytic poliomyelitis (VAPP).
• Wild Poliovirus Count Dashboard Real-time data dashboard tracking wild poliovirus cases and environmental samples globally, providing country-level case counts and epidemiological data for monitoring eradication progress.
• Circulating Vaccine-Derived Poliovirus Count Dashboard Dashboard tracking vaccine-derived poliovirus (VDPV) cases globally and monitoring variant poliovirus outbreaks and transmission patterns.
• Polio Vaccine Forecasting Dashboard 2026-2030 Power BI-based interactive dashboard providing multi-year estimates of polio vaccine requirements globally, regionally, and at country level for routine and supplementary immunization; supports vaccine supply planning.
• Polio Antivirals Research Program Research program developing antiviral treatments (capsid inhibitors and protease inhibitors such as pocapavir and V-7404) to minimize the risk from immune-deficient poliovirus excretors, intended for use in combination therapy.
• Outbreak Response Standard Operating Procedures (SOPs Version 5) SOPs version 5 providing guidelines for rapid and effective response to poliovirus events or outbreaks of both wild and vaccine-derived poliovirus; targeted at countries and health workers conducting outbreak response activities.
• Polio Surveillance System Comprehensive surveillance system comprising Acute Flaccid Paralysis (AFP) surveillance (gold standard for detecting poliomyelitis) and environmental surveillance (testing sewage for poliovirus), supported by the Global Polio Laboratory Network.
• Polio Containment Guidance and Certification Scheme Biosafety and biosecurity requirements for laboratories, vaccine production sites, and facilities handling polioviruses; includes the Containment Certification Scheme (CCS), national inventories, and facility certification against WHO guidance.

Quantifiable outcome

• 99.9% reduction in global polio cases since 1988
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Gavi, the Vaccine AlliancecoreStrategic or Co-development Partner · 1 March 2019Gavi joined GPEI in March 2019 and supports IPV inclusion in routine immunization programs. Fastest global introduction of IPV in 71 Gavi-supported countries by 2019. Collaborates on strengthening health systems.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO coordinates major strategic planning, management and administration. Provides surveillance, technical support to ministries, training, resource mobilization, and serves as secretariat to certification process.
• Rotary InternationalcoreStrategic or Co-development PartnerRotary is the world's first and largest humanitarian service organization with 1.2 million members. Founded PolioPlus in 1985 and has contributed over $2.7 billion and countless volunteer hours. Primary responsibilities include fundraising, advocacy, and volunteer recruitment.
• US Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerCDC provides scientific and technical expertise through Global Immunization Division, Polio and Picornavirus Laboratory, and STOP teams. Supplies diagnostic services and genomic sequencing to guide eradication efforts.
• United Nations Children's Fund (UNICEF)coreStrategic or Co-development PartnerUNICEF procures and distributes polio vaccines for routine and supplementary immunizations. Supports implementation of NIDs and sub-NIDs, develops communication strategies, and helps access hard-to-reach areas including conflict zones.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Rotary International: Service organization that catalyzed GPEI's founding through PolioPlus in 1985 and remains a core partner and largest private-sector donor ($2.7B+ contributed). Compares as a major polio-specific funding and advocacy organization.
• World Health Organization (WHO): UN specialized agency for international public health; houses the GPEI secretariat and coordinates global health initiatives across many diseases. Operates on a much broader mandate and provides the institutional backbone for GPEI's operations.
• US Centers for Disease Control and Prevention (CDC): US federal agency providing scientific, technical, and laboratory expertise to GPEI including genomic sequencing and STOP field teams. Operates a much broader disease control mandate but is one of GPEI's six core partners.
• UNICEF Supply Division: UN agency that procures and distributes polio vaccines globally for GPEI; runs one of the world's largest vaccine supply chains serving routine immunization across all UN member states. Directly comparable logistics and procurement operations.

Direct peers

• The Global Fund to Fight AIDS, Tuberculosis and Malaria: Public-private partnership financing country-led responses to AIDS, TB, and malaria with a similar multi-donor funding model, governance board structure, and country-implementation approach. Comparable scale and architecture to GPEI.
• Measles & Rubella Initiative: Multi-partner coalition (including WHO, UNICEF, Gates Foundation, CDC) focused on measles and rubella elimination. Closest functional analog to GPEI - a multi-partner eradication-style initiative with similar surveillance and mass vaccination campaign approach for a different vaccine-preventable disease.
• Gavi, the Vaccine Alliance: Core GPEI partner since 2019; a public-private partnership that funds vaccine introduction and immunization in lower-income countries. Operates a similar donor-funded multilateral model targeting the same end-beneficiaries (children in low-income countries) and overlapping governance with GPEI.

Others

• Bill & Melinda Gates Foundation Global Development Program: Major GPEI funder ($1.2B pledged in 2025) and core partner; the foundation's Global Development division funds numerous disease eradication and global health initiatives. Comparable funder/payer role across many similar partnerships.

Emerging players

• Coalition for Epidemic Preparedness Innovations (CEPI): Public-private coalition funding vaccine development against emerging epidemic threats. Comparable public-private funding model and vaccine-development mandate, with partial overlap on outbreak preparedness and response.
• Drugs for Neglected Diseases initiative (DNDi): Non-profit product development partnership working on treatments for neglected diseases. Shares the public-private donor-funded, multi-partner R&D model that GPEI employs for polio antivirals and vaccine innovation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=VkQtHY8G3MM
• LinkedInlinkedin.com/company/global-polio-eradication-initiative-gpei

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Polio Eradication